Royal Bank of Canada
LPCN icon

Royal Bank of Canada’s Lipocine LPCN Stock Holding History

Royal Bank of Canada’s Portfolio LPCN Stock Details LPCN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Sell
50
-23
-32% -$200 ﹤0.01% 7435
2025
Q4 		$1K Buy
73
+72
+7,200% +$242 ﹤0.01% 7011
2025
Q3 		$0 Buy
+1
New +$3 ﹤0.01% 7335
2024
Q3 		– Sell
-9
Closed – – 7170
2024
Q2 		$0 Sell
9
-5
-36% -$31 ﹤0.01% 7328
2024
Q1 		$0 Sell
14
-77
-85% -$300 ﹤0.01% 7331
2023
Q4 		$0 Buy
91
+14
+18% +$37 ﹤0.01% 7375
2023
Q3 		$0 Sell
77
-4
-5% -$17 ﹤0.01% 7347
2023
Q2 		$0 Buy
+81
New +$381 ﹤0.01% 7470
2022
Q4 		– Sell
-12
Closed – – 7500
2022
Q3 		$0 Buy
+12
New +$134 ﹤0.01% 7660
2021
Q1 		– Sell
-118
Closed -$3K – 7570
2020
Q4 		$3K Hold
118
– – ﹤0.01% 6799
2020
Q3 		$3K Buy
+118
New +$3.13K ﹤0.01% 6246
2017
Q2 		– Sell
-32
Closed -$2K – 6671
2017
Q1 		$2K Sell
32
-33
-51% -$2.14K ﹤0.01% 6427
2016
Q4 		$4K Buy
+65
New +$4.12K ﹤0.01% 6355
2015
Q1 		– Sell
-4
Closed – – 6289
2014
Q4 		$0 Buy
+4
New +$338 ﹤0.01% 6242

Other funds holding LPCN

IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
SC
Stempoint Capital New York $522M AUM 281.95% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
SFCM
Seven Fleet Capital Management Mountain View, California $318M AUM
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return

Royal Bank of Canada's LPCN Position: Q1 2026 in Review

Royal Bank of Canada reduced its Lipocine (LPCN) stake by 32% in Q1 2026, selling an estimated $200 and leaving 50 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #7435.

Royal Bank of Canada first reported a position in LPCN in Q4 2014 and has held it in 14 quarters since. The position peaked at $4K in Q4 2016. 47 funds tracked by Wall St. Rank hold LPCN as of Q1 2026.

  • Royal Bank of Canada held 50 shares of Lipocine worth $0 as of Q1 2026.
  • Royal Bank of Canada sold 23 Lipocine shares in Q1 2026, an estimated $200.
  • Lipocine made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #7435 holding.
  • Royal Bank of Canada first reported a position in Lipocine in Q4 2014 and has held it in 14 quarters since.
  • Royal Bank of Canada's Lipocine position peaked at $4K in Q4 2016.
  • 47 funds tracked by Wall St. Rank held Lipocine as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.